Contents:
The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. Could possibly test the sma confluence but I think it sees $24 if/when it breaks the weekly trend line.
According to 11 stock analysts, the average 12-month stock price forecast for IRWD stock is $13.01, which predicts an increase of 25.58%. Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal products. The company was founded on January 5, 1998 and is headquartered in Boston, MA.
Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. 3 analysts have issued 12 month target prices for Ironwood Pharmaceuticals’ shares. Their IRWD share price forecasts range from $13.00 to $16.00. On average, they expect the company’s stock price to reach $14.67 in the next twelve months.
To see all exchange delays and terms of use please see Barchart’s disclaimer. The average one-year price target for Ironwood Pharmaceuticals is $13.00 The forecasts range from a low of $9.09 to a high of $16.80. Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic… Ironwood Pharmaceuticals engages in the research, development, and commercialization of human therapeutic products, with a key focus being the treatment of adult men and women suffering from irritable bowel syndrome. The company was founded in 1998 and is based in Cambridge, Massachusetts.
Some negative signals were issued as well, and these may have some influence on the near short-term development. The Ironwood Pharmaceuticals stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $10.60 and $11.20. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence . The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain co…
Analyst rating
On average, Wall Street analysts predict that Ironwood Pharmaceuticals’s share price could reach $14.50 by Aug 16, 2023. The average Ironwood Pharmaceuticals stock price prediction should you buy individual stocks or stick to mutual funds forecasts a potential upside of 38.49% from the current IRWD share price of $10.47. Xencor witnessed a jump in share price last session on above-average trading volume.
Ironwood Pharmaceuticals finds support from accumulated volume at $10.43 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. Ironwood doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. 15 people have searched for IRWD on MarketBeat in the last 30 days. Ironwood Pharmaceuticals does not have a long track record of dividend growth. Short interest in Ironwood Pharmaceuticals has recently increased by 1.38%, indicating that investor sentiment is decreasing.
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.IRWD has a Quality Grade of B, ranking ahead of 94.53% of graded US stocks. Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for IRWD comes in at 14.72% — higher than that of 88.19% of stocks in our set. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity.
Ironwood Pharmaceuticals (IRWD) Misses Q2 Earnings and Revenue Estimates
This suggests a possible upside of 40.5% from the stock’s current price. View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts. Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal products.
IRWDAbsolutely love the r/r this small hourly breakout provides. One share of IRWD stock can currently be purchased for approximately $10.44. Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat’s FREE daily newsletter.
Here’s what to expect from Ironwood Pharmaceuticals A’s earnings report
The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. In 2025, IRWD is forecast to generate $81,025,468,978 in revenue, with the lowest revenue forecast at $81,025,468,978 and the highest revenue forecast at $81,025,468,978. In 2025, IRWD is forecast to generate $235,861,810 in earnings, with the lowest earnings forecast at $235,861,810 and the highest earnings forecast at $235,861,810. Highlights important summary options statistics to provide a forward looking indication of investors’ sentiment. Live educational sessions using site features to explore today’s markets.
Below are the latest news stories about IRONWOOD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IRWD as an investment opportunity. Over the past 34 months, IRWD’s revenue has gone down $29,030,000.The table below shows IRWD’s growth in key financial areas . Over the past 159 months, IRWD’s price/earnings ratio has gone up 24.9. IRWD’s price/sales ratio is 4; this is 122.22% higher than that of the median Healthcare stock.
- 7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com.
- It develops and commercializes GI product opportunities in areas of significant unmet need, leveraging its demonstrated expertise and capabilities in GI diseases.
- Ironwood Pharmaceuticals does not have a long track record of dividend growth.
- This suggests a possible upside of 40.5% from the stock’s current price.
While AI can uncover precious insights, for companies that have not worked with AI previously, this can mean a complete reorganization of their data foundation. From drug discovery to manufacturing and commercialization, technology is powering the industry through an era of unprecedented change. All values as of most recently reported quarter unless otherwise noted.
Moody’s Daily Credit Risk Score
This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies. According to analysts’ consensus price target of $14.67, Ironwood Pharmaceuticals has a forecasted upside of 41.4% from its current price of $10.37.
Analyst Coverage
With a year-over-year growth in debt of -12.82%, IRONWOOD PHARMACEUTICALS INC’s debt growth rate surpasses only 20.09% of about US stocks. IRWD’s current lowest rank is in the Sentiment metric (where it is better than 8.92% of US stocks). This means that this stock is suited as a new addition to your portfolio as trading bullish markets is always a lot easier. Ironwood Pharmaceuticals Inc – Class A stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Hold/Accumulate candidate.
Ironwood Pharmaceuticals Inc. shares surged 3.5% in premarket trade Monday, after the company reported positive results in mid-stage trials of a treatment for diabetes with hypertension. Real-time analyst ratings, insider transactions, earnings data, and more. Ironwood Pharmaceuticals updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $420.00 million-$435.00 million, compared to the consensus revenue estimate of $426.76 million.
Money Flow Uptick/Downtick RatioMoney flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. The average analyst rating for IRWD stock from 11 stock analysts is “Buy”. This means that analysts believe this stock is likely to outperform the market over the next twelve months. Vertex Pharmaceuticals Inc. shares surged 1.2% in premarket trade Wednesday after the company announced that Tom Graney would be its new chief financial officer and senior vice president, starting September 13.
Dow Gains 594 Points as the Market Gets Its Mojo Back
Ironwood Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings. On average, 2 Wall Street analysts forecast IRWD’s revenue for 2024 to be $76,274,318,000, with the lowest IRWD revenue forecast at $75,855,162,273, and the highest IRWD revenue forecast https://day-trading.info/ at $76,693,627,885. On average, 1 Wall Street analyst forecast IRWD’s earnings for 2024 to be $214,279,684, with the lowest IRWD earnings forecast at $214,279,684, and the highest IRWD earnings forecast at $214,279,684. The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.
It develops and commercializes GI product opportunities in areas of significant unmet need, leveraging its demonstrated expertise and capabilities in GI diseases. LINZESS , its commercial product, in a class of GI medicines called guanylate cyclase type C agonists (GC-C agonists) and is… U.S. market indexes rose on Thursday morning as investors were encouraged by several key earnings reports and Treasury yields continued to climb. Though Ironwood missed both Q4 earnings and sales estimates, the total prescription demand for the sole-marketed drug Linzess rose 9% year over year. After months of turmoil over its drug-price increases and business practices, Valeant Pharmaceuticals International Inc. will try to show this week that it’s getting back to business as usual. Ironwood Pharmaceuticals Inc. reported fourth quarter revenue and adjusted earnings above analyst expectations.
It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services.